Brain Inflammation: The Hidden Driver of Neurodegenerative Diseases
Scientists have long been searching for effective ways to control brain inflammation. Growing evidence suggests that chronic neuroinflammation is a major driver of conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, depression, and schizophrenia. However, treatment options targeting this process remain extremely limited.
Recently, a research team led by Professor Nicholas Barnes at the University of Birmingham published an important study in the journal Brain. They discovered that blocking a protein called the P2X7 receptor can significantly reduce inflammation in human brain tissue. This finding offers hope for developing entirely new therapeutic approaches to neuroinflammation.
P2X7 Receptor: A Key Switch for Brain Inflammation
The P2X7 receptor is a receptor that triggers inflammatory signaling. The research team conducted in-depth studies using live cultures of human brain cells and slices of brain tissue obtained during neurosurgery.
They found that P2X7 receptors promote the release of cytokines—proteins that regulate inflammatory responses. When researchers used a specific antagonist to block the receptor, the inflammatory response in human brain tissue dropped significantly.
Professor Barnes said: "This exciting discovery marks a major step toward repurposing existing therapeutics to combat neuroinflammation at its source. The identification of this receptor could have far-reaching implications for some of the most debilitating and widespread brain disorders such as Alzheimer's disease, Parkinson's, and multiple sclerosis, or inflammation-linked psychiatric conditions like schizophrenia and depression."
Microglia: The Brain's Immune Guardians
A major part of this work involved microglia—immune cells that help coordinate the brain's response to injury and inflammation. To study how these cells react to inflammatory signals, the researchers developed a method for converting a type of white blood cell into microglia.
This process mirrors a cellular transformation that has recently been identified as occurring naturally in the brain during human aging. The team started with human peripheral monocytes collected from blood samples and converted them into microglia-like cells, providing a way to examine how human microglia may respond to inflammatory signals with precision.
When the researchers applied the P2X7 receptor antagonist, they were able to interfere with signals released by microglia as the cells became damaged and died.
Professor Barnes explained: "Studying human microglia has long been a major challenge: once removed from their native brain environment, they rapidly lose their defining characteristics. Our approach involved the use of monocyte-derived microglia which provide a powerful, scalable, and virtually unlimited platform for studying human microglial biology with unprecedented precision."
From Lab Models to Human Brain Tissue: A Successful Translational Validation
After identifying the response in lab-grown microglia-like cells, the researchers tested whether the same findings could be reproduced in human brain tissue obtained through neurosurgical procedures. The results were encouraging—success was also achieved in human brain tissue, providing strong support for further investigation.
Professor Barnes said: "Having identified the response in the human monocyte-derived microglia, this provided the impetus to translate these findings with human brain obtained following neurosurgical procedures. This successful translation means the next stage for this research is the development of clinical trials in patients with neurodegenerative conditions and patients with TBI where there are no effective pharmacological treatments to reduce the neuroinflammation and arising damage."
Future Outlook: The Potential of Repurposing Existing Drugs
A significant advantage of this research is that the P2X7 receptor can already be blocked by existing drugs. This means researchers may be able to rapidly advance clinical trials through a "repurposing" strategy, bringing new treatment options to patients.
Currently, the team is working to promote the launch of clinical trials, aiming to provide new hope for patients with Alzheimer's disease, Parkinson's disease, traumatic brain injury, and other conditions lacking effective anti-inflammatory treatments.
Focus on Brain Health: Start with Daily Monitoring
Brain health is closely related to overall health. Maintaining good sleep, controlling blood pressure and blood sugar levels, and engaging in moderate exercise can all help reduce the risk of neuroinflammation. You can use the Xiaoshu Health App to sync with Apple Health and track key metrics such as sleep quality, heart rate variability, and step count, gaining a comprehensive understanding of your physical condition and safeguarding your brain health.